Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

How much GMP do we need to infuse contaminated HPC and DLI products?

Bone Marrow Transplantation volume 40, pages 389–390 (2007)Cite this article

We read with interest the article by Kelly et al.1 which emphasizes the importance of the clinical impact of infusion of haemopoietic progenitor cells (HPC)/donor lymphocytes (DLI) potentially contaminated with bacteria. They suggest that infusions of HPC/DLI, contaminated with bacteria do not cause significant clinical sequelae. However, there is no randomized trial that deals with this important topic. The increasing manipulation of HPC for transplantation and immunotherapy in clinical practice highlights the importance of maintaining sterility of the processed products.2 The sterility of HPC/DLI is of particular relevance because of the implementation of the EU directive 2004/23/EC in April 2006, which specifies good manufacturing practice (GMP), including the processing of haemopoietic progenitor cells-apheresis (HPC-A), haemopoietic progenitor cells-marrow (HPC-M) and DLI in certified clean rooms.3, 4, 5, 6, 7

Kelly et al. have demonstrated in a retrospective analysis that the contamination rate is 1.0% in over 15 years of activity and that the infusion of contaminated HPC rarely results in unfavourable outcome for the recipient in the autologous or allogeneic setting. They suggest close monitoring and no necessity for pre-emptive antibiotic therapy with infusion of microbial-positive products.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Kelly M, Roy DC, Labbe AC, Laverdiere M . What is the clinical significance of infusing hematopoietic cell grafts contaminated with bacteria? Bone Marrow Transplant 2006; 38: 183–188.

    Article  CAS  Google Scholar 

  2. Introna M, Barbui AM, Golay J, Rambaldi A . Innovative cell-based therapies in onco-hematology: what are the clinical facts? Haematologica 2004; 89: 1253–1260.

    PubMed  Google Scholar 

  3. US Food and Drug Administration. 21 CFR Part 210-CGMP in manufacturing, Processing, Packing, or holding of drugs.

  4. US Food and Drug Administration. 21 CFR Part 211-CGMP for Finished Pharmaceuticals.

  5. European Union. Directive 2004/23/EC of the European parliament and of the Council of 31 March 2004 on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells.

  6. European Communities. Directive 2001/20/EC of the European parliament and of the council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the member states relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use.

  7. European Union. Commission Directive 2003/94/EC of 8 October 2003 laying down the principles and guidelines of good manufacturing practice in respect of medicinal products for human use and investigational medicinal products for human use.

  8. Kamble R, Pant S, Selby GB, Kharfan-Dabaja MA, Sethi S, Kratochvil K . Microbial contamination of hematopoietic progenitor cell grafts-incidence, clinical outcome, and cost-effectiveness: an analysis of 735 grafts. Transfusion 2005; 45: 874–878.

    Article  Google Scholar 

  9. Ritter M, Schwedler J, Beyer J, Movassaghi K, Mutters R, Neubauer A . Bacterial contamination of ex vivo processed PBPC products under clean room conditions. Transfusion 2003; 43: 1587–1595.

    Article  Google Scholar 

  10. Foundation for the Accreditation of Cellular Therapy and the Joint Accreditation Committee – ISCT and EBMT. International Standards for Cellular Therapy Product Collection, Processing and Administration, 3rd edn, 2006.

Download references

Author information

Authors and Affiliations

  1. Cryobiology Laboratory Stem Cell Facility, St James Hospital, Dublin, Ireland

    L Forte, N Gardiner & S R McCann

  2. Department of Microbiology, Central Pathology Laboratory, St James Hospital, Dublin, Ireland

    B O'Connell

Authors
  1. L Forte
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N Gardiner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B O'Connell
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S R McCann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S R McCann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Forte, L., Gardiner, N., O'Connell, B. et al. How much GMP do we need to infuse contaminated HPC and DLI products?. Bone Marrow Transplant 40, 389–390 (2007). https://doi.org/10.1038/sj.bmt.1705723

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705723

Search

Advanced search

Quick links